Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2093-2102

  Quint, Karl ^a   Tonigold, Manuel ^a   Di Fazio, Pietro ^a   Montalbano, Roberta ^a   Lingelbach, Susanne ^a   Rückert, Felix ^c   Alinger, Beate ^b   Ocker, Matthias ^a   Neureiter, Daniel ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoresistance; Differentiation; Embryonic; Epithelial mesenchymal transition; Gemcitabine; Pancreatic cancer

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; HERMES ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL; CANCER STEM CELL; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DNA REPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; IC 50; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA PURIFICATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DEOXYCYTIDINE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; WOUND HEALING;

EID: 84869825723     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1648     Document Type: Article

References (43)

1. Ellison LF and Wilkins K: An update on cancer survival. Health Rep 21: 55-60, 2010.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007. (Pubitemid 46972777)
5. Conroy T, Paillot B, François E, et al: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 23: 1228-1236, 2005. (Pubitemid 46202280)
6. Ducreux M, Boige V and Malka D: Treatment of advanced pancreatic cancer. Semin Oncol 34: S25-S30, 2007. (Pubitemid 46590362)
7. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
8. Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
9. Klonisch T, Wiechec E, Hombach-Klonisch S, et al: Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 14: 450-460, 2008.
10. Liu QH, Zhang J, Zhao CY, et al: Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Lett 314: 119-125, 2012.
11. Bonner-Weir S and Sharma A: Pancreatic stem cells. J Pathol 197: 519-526, 2002.
12. O'Brien CA, Kreso A and Jamieson CH: Cancer stem cells and self-renewal. Clin Cancer Res 16: 3113-3120, 2010.
13. Zhang YQ, Kritzik M and Sarvetnick N: Identification and expansion of pancreatic stem/progenitor cells. J Cell Mol Med 9: 331-344, 2005.
14. Lee CJ, Dosch J and Simeone DM: Pancreatic cancer stem cells. J Clin Oncol 26: 2806-2812, 2008.
15. Quante M and Wang TC: Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 6: 724-737, 2009.
16. Wang JC and Dick JE: Cancer stem cells: lessons from leukemia. Trends Cell Biol 15: 494-501, 2005. (Pubitemid 41253469)
17. Zou GM: Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol 217: 598-604, 2008.
18. Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24: 506-513, 2006. (Pubitemid 44464754)
19. Haraguchi N, Inoue H, Tanaka F, et al: Cancer stem cells in human gastrointestinal cancers. Hum Cell 19: 24-29, 2006.
20. Hermann PC, Bhaskar S, Cioffi M and Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol 20: 77-84, 2010.
21. Zhou J, Wang CY, Liu T, et al: Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14: 925-930, 2008. (Pubitemid 351325033)
22. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
23. Arumugam T, Ramachandran V, Fournier KF, et al: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828, 2009.
24. Kim MP and Gallick GE: Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14: 1284-1285, 2008. (Pubitemid 351413904)
25. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008. (Pubitemid 351636299)
26. Rückert F, Werner K, Aust D, et al: Immunohistological analysis of six new primary pancreatic adenocarcinoma cell lines. Global J Biochem 3: 11, 2012.
27. Rückert F, Aust D, Böhme I, et al: Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res 172: 29-39, 2012.
28. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
29. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
30. Ke N, Wang X, Xu X and Abassi YA: The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 740: 33-43, 2011.
31. Sipos B, Moser S, Kalthoff H, et al: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-52, 2003. (Pubitemid 36718311)
32. Neureiter D, Zopf S, Dimmler A, et al: Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology 5: 387-397, 2005. (Pubitemid 41160276)
33. Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-2331, 2009.
34. Du Z, Qin R, Wei C, et al: Pancreatic cancer cells resistant to chemoradiotherapy rich in 'stem-cell-like' tumor cells. Dig Dis Sci 56: 741-750, 2011.
35. Quint K, Stintzing S, Alinger B, et al: The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 9: 116-26, 2009.
36. Wen J, Park JY, Park KH, et al: Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 39: 622-626, 2010.
37. Fan CM and Tessier-Lavigne M: Patterning of mammalian somites by surface ectoderm and notochord: evidence for sclerotome induction by a hedgehog homolog. Cell 79: 1175-1186, 1994.
38. Li X, Deng W, Lobo-Ruppert S and Ruppert J: Gli1 acts through Snail and E-cadherin to promote nuclear signaling by β-catenin. Oncogene 26: 4489-4498, 2007. (Pubitemid 47037042)
39. Hotz B, Arndt M, Dullat S, et al: Epithelial to mesenchymal transition: expression of the regulators Snail, Slug, and Twist in pancreatic cancer. Clin Cancer Res 13: 4769-4776, 2007. (Pubitemid 47294783)
40. Missol-Kolka E, Karbanová J, Janich P, et al: Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate 71: 254-267, 2011.
41. Karbanová J, Missol-Kolka E, Fonseca AV, et al: The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56: 977-993, 2008.
42. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the 'stem cell marker' CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48, 2008.
43. + cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.